A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still ...

In a report released yesterday, Charlie CY Yang from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research ...

BofA analyst Charlie Yang raised the firm’s price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The ...

A previous pilot study examining the company’s SJP-001 compound found it was able to cut hangover symptoms such as headaches, ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for ...

Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

Uncover hidden gems in the stock market with the 'Undercovered Dozen' series featuring undervalued stocks with potential for ...

On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

After a long bull run, most stocks offer uninspiring dividend yields. Brookfield Infrastructure, Realty Income, and Royalty Pharma are dividend-paying stocks that offer yields above 3% at recent ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...